TW-37

Catalog No.S1121

TW-37 Chemical Structure

Molecular Weight(MW): 573.7

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 146 In stock
USD 160 In stock
USD 680 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 24 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Targets
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
In vitro

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell M{LNXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWTJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNjDuUS=> NUjtTVQ4W0GQR1XS
human Ca9-22 cell NVXGSXBTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV:5VHdEUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh{IH7N MYHTRW5ITVJ?
human CHL-1 cell NWrMbo0yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NETIOFRKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvQSCwTR?= NVzOO45yW0GQR1XS
human A549 cell MoLFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUntb295UW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvODlibl2= MWfTRW5ITVJ?
human RKO cell M4ixVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF3LkG3JI5O NVLy[5JEW0GQR1XS
human GCIY cell NF7Ve3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD64N{BvVQ>? M{T3enNCVkeHUh?=
human BHT-101 cell NXHVSVA5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLXZY5uUW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEOgcm0> M3flbnNCVkeHUh?=
human Hs-578-T cell NHP5Z3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjyTY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjV7IH7N NWLURYR{W0GQR1XS
human SK-UT-1 cell NF;reXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mke1TY5pcWKrdHnvckBw\iCqdX3hckBUUy2XVD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPjhibl2= MWTTRW5ITVJ?
human NB7 cell M4OzT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnrqTY5pcWKrdHnvckBw\iCqdX3hckBPSjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OT6yPEBvVQ>? NVrVcHZPW0GQR1XS
human YKG-1 cell MnzaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HUXWlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU44PiCwTR?= MlLiV2FPT0WU
human HuH-7 cell MnrSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlLVTY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOyMlgzKG6P M2jrdXNCVkeHUh?=
human SAS cell Mke1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml7qTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6xPEBvVQ>? Mn3VV2FPT0WU
human UACC-62 cell M1\ndGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWn0WmxFUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVYzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwM{Wgcm0> MlrZV2FPT0WU
human AGS cell MkXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jxRWlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{euOVMhdk1? M1fxPHNCVkeHUh?=
human SK-MEL-30 cell NGrod4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3;LN2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzdwOUegcm0> MXrTRW5ITVJ?
human A427 cell NWDkWWZoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnL5TY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NESuOlkhdk1? M{LNd3NCVkeHUh?=
human DU-145 cell NIDFOpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWyMlE{KG6P NYjXT3hJW0GQR1XS
human HCT-116 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4TVPGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUzNjZ4IH7N NVvxWJcxW0GQR1XS
human A673 cell NXHXeotyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnsNplKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N{45PSCwTR?= M2HpeXNCVkeHUh?=
human SF126 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTocY5jUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU4NjB5IH7N NEDBfGxUSU6JRWK=
human SW872 cell NEPKO2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX\PRlFXUW6qaXLpeIlwdiCxZjDoeY1idiCVV{i3NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU5Njlibl2= NGnrepZUSU6JRWK=
human NCI-H1581 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlPZTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1PFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Py54NDDuUS=> M{DvPHNCVkeHUh?=
human SK-MEL-5 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnZcGRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwMkWgcm0> M{HVZXNCVkeHUh?=
human CP50-MEL-B cell NEfFWG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnNd2ZJUW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkmuOVkhdk1? MV;TRW5ITVJ?
human YH-13 cell NGnhNVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\X[WlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23NE42QSCwTR?= MnfuV2FPT0WU
human LXF-289 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV\4S5NXUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PzJwOEWgcm0> NWHMN21vW0GQR1XS
human MC-IXC cell M4TMdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe1MlM{KG6P MlvwV2FPT0WU
human NB14 cell M1mxVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HHfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe2MlQ2KG6P NXTKPWJjW0GQR1XS
human HEC-1 cell MljoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGhGSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OEGuN|chdk1? MoDyV2FPT0WU
human U-87-MG cell M2G0e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfLS5VKdmirYnn0bY9vKG:oIHj1cYFvKFVvOEetUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Oi5{NDDuUS=> MmnqV2FPT0WU
human HOS cell MmHIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFK1cFRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi0MlcyKG6P NXfyN5dlW0GQR1XS
human HUTU-80 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGPXcWNKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Py5yMTDuUS=> MYPTRW5ITVJ?
human A375 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;TU3FCUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFgvQDNibl2= MlnyV2FPT0WU
human A204 cell NIXqNHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Nz64OEBvVQ>? MUHTRW5ITVJ?
human GB-1 cell M3;lXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmPETY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUiuOlkhdk1? NUGwNXo5W0GQR1XS
human MDA-MB-231 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3:4NmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC4NFch|ryP MUfTRW5ITVJ?
human SW982 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNVA4KM7:TR?= NWKyeZFDW0GQR1XS
human SW756 cell NYXGcpc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MojOTY5pcWKrdHnvckBw\iCqdX3hckBUXzd3NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzOzZizszN M4Tyc3NCVkeHUh?=
human MG-63 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHlVpJKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTJ2ODFOwG0> NVmwVGtiW0GQR1XS
human Daoy cell MlzwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjyTY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOFA4OyEQvF2= NITtNJdUSU6JRWK=
human MDA-MB-453 cell NGr3eYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn3ITY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFU{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUG4PEDPxE1? M2TGe3NCVkeHUh?=
human HT-144 cell M3LMWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoDaTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zNESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjBzIN88US=> NFO0TodUSU6JRWK=
human LoVo cell NWXyU4lYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NU\tfotnUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjB7MzFOwG0> NXnNTWR[W0GQR1XS
human NY cell MlHSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYTxWoJnUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc4PjJizszN MkPsV2FPT0WU
human SW1783 cell Ml7ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NY\wSWRMUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3PFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJzM{CxJO69VQ>? M{PIVXNCVkeHUh?=
human A2780 cell M1rQWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4\vfGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyQDR4IN88US=> MWHTRW5ITVJ?
human MDA-MB-361 cell NH7DRZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{DKT2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK2OEDPxE1? NFrMeW1USU6JRWK=
human RPMI-2650 cell M4L4dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{nMNGlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST2yOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{izNUDPxE1? M1jud3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

Protocol

Kinase Assay:[1]
+ Expand

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
Cell Research:[2]
+ Expand
  • Cell lines: HDMECs
  • Concentrations: 0 - 100 μM
  • Incubation Time: 96 hours
  • Method: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • Formulation: TW-37 is resuspended in 1:1 Tween 80/ethanol (diluted 10-fold in 0.9% saline before use).
  • Dosages: ~40 mg/kg
  • Administration: Administered via i.v. or i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 573.7
Formula

C33H35NO6S

CAS No. 877877-35-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID